Bo Gao
The University of Sydney(AU)Guiyang Medical University(CN)Regeneron (United States)(US)Shanghai University of Sport(CN)Blacktown & Mount Druitt Hospital(AU)Westmead Hospital(AU)Yuhuangding Hospital(CN)Suzhou University of Science and Technology(CN)Beihai People's Hospital(CN)Affiliated Hospital of Guizhou Medical University(CN)First Affiliated Hospital of Bengbu Medical College(CN)Xijing Hospital(CN)Liaoning Cancer Hospital & Institute(CN)Ocean University of China(CN)Chongqing Medical University(CN)China Medical University(CN)Air Force Medical University(CN)
Publications by Year
Research Areas
Neurological Complications and Syndromes, Cancer Immunotherapy and Biomarkers, Moyamoya disease diagnosis and treatment, Lung Cancer Treatments and Mutations, Cardiac Valve Diseases and Treatments
Most-Cited Works
- → Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study(2019)3,089 cited
- → PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma(2018)1,359 cited
- → Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial(2021)783 cited
- → One-Year Outcomes of the DA VINCI Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema(2012)392 cited
- → Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial(2022)279 cited
- → Altered Spontaneous Brain Activity in Type 2 Diabetes: A Resting-State Functional MRI Study